Search

 
 
 
Kineta Gets $15M in New Cancer Drug Partnership with Pfizer

KINETA GETS $15M IN NEW CANCER DRUG PARTNERSHIP WITH PFIZER

Seattle biotech company Kineta continues to expand its roster of drug development partners, announcing on Monday it has entered into...

 
 
 
15 For '19: Key Clinical Data To Watch For Next Year

15 FOR '19: KEY CLINICAL DATA TO WATCH FOR NEXT YEAR

It can take decades and billions of dollars to develop a drug, and its fate-and often that of its developer-rests in the outcome of...

FDA approves Celltrion, Teva's Rituxan biosimilar, but with a narrow label

FDA APPROVES CELLTRION, TEVA'S RITUXAN BIOSIMILAR, BUT WITH A NARROW LABEL

The agency approved Truxima for three lymphoma indications, whereas European regulators approved it last year for all the same indications...

 
 
 
FDA Approves Roche Drug For All Hemophilia A Patients, But Rivals Loom

FDA APPROVES ROCHE DRUG FOR ALL HEMOPHILIA A PATIENTS, BUT RIVALS LOOM

The treatment landscape for hemophilia is changing fast, and today marks a turning point. The FDA has just cleared Roche to sell its...

 
 
 
Bio Roundup: A Gene Editing 1st, China Rises, Schenkein Steps Away

BIO ROUNDUP: A GENE EDITING 1ST, CHINA RISES, SCHENKEIN STEPS AWAY

If you're still recovering from a Labor Day hangover or busy searching for the identity of the anonymous writer of the anti-Trump op-ed...

 
 
 
After a High-Speed Decade, Agios CEO David Schenkein to Step Aside

AFTER A HIGH-SPEED DECADE, AGIOS CEO DAVID SCHENKEIN TO STEP ASIDE

David Schenkein, the longtime CEO of Agios Pharmaceuticals, will step aside next year after transforming what was once a high-risk...

 
 
 
Bio Roundup: Drug Prices, CRISPR Caveats, Rubius IPO Pop & More

BIO ROUNDUP: DRUG PRICES, CRISPR CAVEATS, RUBIUS IPO POP & MORE

After nearly two years of all smoke, no fire around President Trump's promise to curtail drug prices, there's finally some glimmer...

 
 
 

PROCESS AUTOMATION ENGINEER I/II - GENENTECH - OCEANSIDE, CA

Bachelor's or Master's degree in Engineering (Chemical, Mechanical, Electrical, or Computer Science preferred) and 5 years experience,...

 
 
 
 
 
 
Bio Roundup: Biotech IPOs, Migraine Progress, Takeda Woos Shire & More

BIO ROUNDUP: BIOTECH IPOS, MIGRAINE PROGRESS, TAKEDA WOOS SHIRE & MORE

If the recent IPO activity seems to be on overdrive, it's not your imagination. The number of companies filing to go public in the...

Bio Roundup: CMS Backs Cancer Tests, Right to Try Passes, AbbVie Sinks

BIO ROUNDUP: CMS BACKS CANCER TESTS, RIGHT TO TRY PASSES, ABBVIE SINKS

We'll start this week's roundup with several stories from Washington, D.C. that could have a lasting effect on public health. The FDA...